Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Kristina Lindemann, Susanne Malander, Rene D Christensen, Mansoor R Mirza, Gunnar B Kristensen, Elisabeth Aavall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman, Britta Nordstrøm, Kristina Lindemann, Susanne Malander, Rene D Christensen, Mansoor R Mirza, Gunnar B Kristensen, Elisabeth Aavall-Lundqvist, Ignace Vergote, Per Rosenberg, Karin Boman, Britta Nordstrøm

Abstract

Background: We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma.

Methods: We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients.

Results: Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95% CI: 2.1-3-1). In the ER positive patients the median overall survival (OS) time was 13.3 months (95% CI: 7.7-18.9), in the ER negative patients the corresponding numbers were 6.1 months (95% CI: 4.1-8.2). Treatment with exemestane was well tolerated.

Conclusion: Treatment of estrogen positive advanced or recurrent endometrial cancer with exemestane, an aromatase inhibitor, resulted in a response rate of 10% and lack of progression after 6 months in 35% of the patients.

Trial registration: Trial identification number (Clinical Trials.gov): NCT01965080.Nordic Society of Gynecological Oncology: NSGO-EC-0302.EudraCT number: 2004-001103-35.

Figures

Figure 1
Figure 1
Enrollment, randomization and treatment response.
Figure 2
Figure 2
Progression free survival according to receptor status.
Figure 3
Figure 3
Overall survival according to receptor status.

References

    1. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer J Int Du Cancer. 2010;127(12):2918–2927. doi: 10.1002/ijc.25517.
    1. Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in Norway during 1953-2007 and predictions for 2008-2027. Int J Cancer J Int Du Cancer. 2010;127(11):2661–2668. doi: 10.1002/ijc.25267.
    1. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and-B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112(3):537–542. doi: 10.1016/j.ygyno.2008.10.032.
    1. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–978. doi: 10.1111/j.1525-1438.2007.00897.x.
    1. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2007;106(2):325–333. doi: 10.1016/j.ygyno.2007.03.042.
    1. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma: a review of clinical observations. Acta obstetricia et gynecologica Scandinavica. 1984;63(5):441–450. doi: 10.3109/00016348409156700.
    1. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Critical Rev Oncol/Hematol. 2008;67(3):204–212. doi: 10.1016/j.critrevonc.2008.02.011.
    1. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010;12:CD007926.
    1. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstetrics Gynecol. 1982;59(6):680–686.
    1. Ma BB, Oza A, Eisenhauer E, Stanimir G, Carey M, Chapman W, Latta E, Sidhu K, Powers J, Walsh W. et al.The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the national cancer institute of canada clinical trials group. Int J Gynecol Cancer. 2004;14(4):650–658. doi: 10.1111/j.1048-891X.2004.14419.x.
    1. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2000;78(2):212–216. doi: 10.1006/gyno.2000.5865.
    1. Lintermans A, Neven P, Paridaens R. Drug safety evaluation of exemestane. Expert Opin Drug Safety. 2011;10(3):473–487. doi: 10.1517/14740338.2011.567264.
    1. Nordstrom BM, De Pont Christensen R, Oksefjell H, Kristensen G. Exemestane in advanced and recurrent endometrial carcinoma: a phase II study by NSGO. ASCO Ann Meeting Proc. 2006;24:266s.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC. et al.New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216. doi: 10.1093/jnci/92.3.205.
    1. National Cancer Institute. Common toxicity criteria, toxical scale, version 2.0. . 1999.
    1. Slomovitz BSP, Levenback C, Brown J, Wolf J, Schmeler K, Johnston T, Mura D, Stone RL, Lu K, Coleman RL. Everolimus and letrozole in women with previously treated recurrent endometrial cancer: a multiinstitutional phase II clinical trial. Int J Gynecol Cancer. 2012;22(suppl. 3):8.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다